Ewa J.
- Country
- Poland
- Department
- N/A
Research Overview
- N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
- HepaStem Long-Term Safety Registry – Registry for Patients who have been administered HepaStem
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa in Adults with Biopsy‑Confirmed F2–F3 Metabolic Dysfunction‑Associated Steatohepatitis
Data & Insights
Has run more than one trial at 217 of 380 partner sites.
Specializations
Chronic liver disease and metabolic steatotic liver disease
Clinical research activity centers on MASLD, MASH, NASH, and fibrotic liver disease, with attention to progression, histologic improvement, and prevention of liver-related complications.
- MASH with compensated cirrhosis
- NASH with fibrosis
- Metabolic dysfunction-associated steatotic liver disease
- Fibrosis and liver outcomes
Interest also extends to cirrhosis-associated events and the broader management of chronic liver injury.
Viral hepatitis and hepatitis B cure strategies
The investigator is involved in studies of chronic hepatitis B, HBV infection, and long-term disease control, including approaches aimed at functional cure and durable viral suppression.
- Chronic HBV infection
- Chronic hepatitis B
- Functional cure
- NA-treated HBV
Additional involvement includes chronic hepatitis C virus infection and antiviral innovation in persistent liver disease.
Cholestatic liver disease and bile duct disorders
Research activity includes primary biliary cholangitis, primary sclerosing cholangitis, cholestasis, and related symptoms such as cholestatic pruritus, reflecting a strong therapeutic focus on progressive cholangiopathies.
- Primary sclerosing cholangitis
- Primary biliary cholangitis
- Cholestatic pruritus
- Cholestasis
Work in this area also includes liver-related complications linked to advanced cholestatic disease.
Hepatocellular carcinoma and advanced liver complications
Clinical involvement extends to hepatocellular carcinoma, post-treatment recurrence prevention, and complications of advanced liver disease such as hepatic encephalopathy and esophageal varices.
- Hepatocellular carcinoma
- Hepatic encephalopathy
- Esophageal varices
- Cirrhosis
Interest also includes outcomes in decompensated or compensated cirrhosis and prevention of major liver-related events.
Rare and systemic metabolic disorders
The investigator also participates in research on alpha-1 antitrypsin deficiency-associated liver disease, alcohol-related liver disease, and type 2 diabetes mellitus, highlighting a broader therapeutic scope across hepatic and metabolic conditions.
- Alpha-1 antitrypsin deficiency-associated liver disease
- Alcohol-related liver disease
- Type 2 diabetes mellitus
- Fibroinflammatory liver disease
These activities reflect engagement with liver-directed therapies and metabolic comorbidity management in chronic disease settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.